

Study Number	AALL1331			
NCT #	NCT02101853			
Dataset #	NCT02101853-D1 (Main)			
PMID #	33651090			
Comments: Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).				
Variable Number	Variable Name	Type	Label	Notes
1	USI	Character	USI	
2	consort_elig	Character	Eligibility	
3	consort_p1	Character	Completion of risk assignment	
4	riskgroup	Character	Risk group	
5	consort_p2	Character	Eligibility for randomization among High risk and Intermediate risk patients	
6	consort_p3	Character	Arm randomization and primary analysis eligibility	
7	consort_p4	Character	Received cycle 1 of treatment	
8	consort_p5	Character	Received cycle 2 of treatment	
9	consort_p6	Character	Underwent HSCT	
10	pt_outcome	Character	Patients in the analyses: n=208 for primary analysis, n=45 for exploratory analysis	
11	riskrelsite	Character	Risk group and site of relapse	
12	arm	Character	Treatment Arm	
13	stratum	Character	Stratum	
14	ageyr_enr	Numeric	Age at enrollment in years	
15	agegrp_enr	Character	Age at enrollment group in years	
16	ageyr_dx	Numeric	Age at initial diagnosis in years	
17	agegrp_dx	Character	Age at initial diagnosis group in years	
18	sex	Character	Gender	
19	race	Character	Race	

Study Number	AALL1331			
NCT #	NCT02101853			
Dataset #	NCT02101853-D1 (Main)			
PMID #	33651090			
Comments: Blanks represent missing data or not applicable for analyses. Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).				
20	ethnicity	Character	Ethnicity	
21	relsitime	Character	Site of Relapse	
22	cytogrp	Character	Cytogenetic group	
23	bmtime_mrd	Character	Time to relapse and post reinduction MRD among high risk bone marrow relapse group	
24	mrd_reind	Character	MRD negativity at the end of reinduction	Negative: MRD < 0.01%; Positive: MRD ≥ 0.01% or MRD < 0.1% with sensitivity 1 in 1000
25	mrd_reind_pct	Numeric	MRD % at the end of reinduction	
26	mrd_c1	Character	MRD negativity at the end of cycle 1	Negative: MRD < 0.01%; Positive: MRD ≥ 0.01% or MRD < 0.1% with sensitivity 1 in 1000
27	mrd_c1_pct	Numeric	MRD % at the end of cycle 1	
28	mrd_c2	Character	MRD negativity at the end of cycle 2	Negative: MRD < 0.01%; Positive: MRD ≥ 0.01% or MRD < 0.1% with sensitivity 1 in 1000
29	mrd_c2_pct	Numeric	MRD % at the end of cycle 2	
30	cd19_mrdrecur	Character	CD19 expression for blinatumomab patients with recurrent MRD	
31	relp_c2_mrdrevert	Character	Indicates if patient had a relapse after blinatumomab cycle 2 among patients who had negative MRD in blinatumomab cycle 1 and reverted to positive MRD in cycle 2	

Study Number		AALL1331		
NCT #		NCT02101853		
Dataset #		NCT02101853-D1 (Main)		
PMID #		33651090		
<p>Comments: Blanks represent missing data or not applicable for analyses.  Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).</p>				
32	hsct	Character	Indicates if patient underwent hematopoietic stem cell transplant among randomized patients	
33	eventype	Character	First event type	
34	dfsi	Numeric	Disease free survival from randomization	0-censor, 1-event
35	yrsdfs	Numeric	Years to disease free survival from randomization	
36	osi	Numeric	Overall Survival from randomization	0-censor, 1-death
37	yrsos	Numeric	Years to overall survival from randomization	
38	cycle1	Character	Received cycle 1 of treatment	
39	cycle2	Character	Received cycle 2 of treatment	
40	anyaecycle1	Character	Indicates if patient had any grade AEs during cycle 1	
41	anyaecycle2	Character	Indicates if patient had any grade AEs during cycle 2	
42	anyae	Character	Indicates if patient had any grade AEs during cycle1/cycle 2	
43	grade3cycle1	Character	Indicates if patient had grade 3+ AEs during cycle 1	
44	grade3cycle2	Character	Indicates if patient had grade 3+ AEs during cycle 2	
45	grade3	Character	Indicates if patient had grade 3+ AEs during cycle1/cycle 2	
46	toxdeath	Character	Indicates if patient had toxic death during cycle1/cycle 2	

Study Number		AALL1331	
NCT #		NCT02101853	
Dataset #		NCT02101853-D1 (Main)	
PMID #		33651090	
<p>Comments: Blanks represent missing data or not applicable for analyses.  Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).</p>			
47	wdltfu	Character	Withdrew consent or lost to follow-up <2 years of follow-up
48	salvtx	Character	Received salvage therapy among early treatment failure patients
49	tf_cns	Character	Indicates if early treatment failure patients had CNS-3 disease
50	tf_remission	Character	Indicates if early treatment failure patients had morphologic remission after 1 cycle of salvage blinatumomab
51	tf_nmr1	Character	Indicates if early treatment failure patients had negative MRD after 1 cycle of salvage blinatumomab
52	tf_nmr2	Character	Indicates if early treatment failure patients had negative MRD after 2 cycles of salvage blinatumomab
53	tf_hsct	Character	Indicates if early treatment failure patients proceeded to transplant
54	dose_red_c1	Character	Indicates if patient had blinatumomab dose reduction during cycle 1
55	dose_red_c2	Character	Indicates if patient had blinatumomab dose reduction during cycle 2